Development and internal validation of a non-invasive clinical tool to predict sufficient omega-3 levels in early pregnancy

Table 7 Performance measures (95% confidence interval) assessing clinical utility

Model Predictors^*	Estimated n-3 intake (mg/week)	NB	TPR at 10% FPR	TNR at 10% FNR	PPV	NPV
Dietary and supplementary intake of total n-3	767.8	0.306 (0.303–0.310)	0.376 (0.369–0.383)	0.360 (0.353–0.367)	0.725 (0.723–0.728)	0.719 (0.715–0.724)
Dietary and supplementary intake of total n-3 with 1.0% ALA conversion	797.0	0.299 (0.296–0.302)	0.359 (0.352–0.365)	0.361 (0.355–0.368)	0.721 (0.719–0.724)	0.706 (0.701–0.710)
Dietary and supplementary intake of total n-3 LCPUFA	630.1	0.295 (0.292–0.298)	0.420 (0.414–0.426)	0.363 (0.357–0.370)	0.706 (0.703–0.708)	0.734 (0.728–0.739)
Dietary and supplementary intake of total n-3 with 1.0% ALA conversion	670.9	0.278 (0.275–0.282)	0.381 (0.375–0.387)	0.367 (0.360–0.373)	0.698 (0.696–0.701)	0.697 (0.692–0.702)
Dietary and supplementary intake of total n-3 LCPUFA	558.1	0.274 (0.271–0.277)	0.396 (0.391–0.401)	0.367 (0.360–0.373)	0.693 (0.690–0.695)	0.701 (0.695–0.706)

^*All models were adjusted for maternal age, BMI, IRSAD and n-3 additions. Dietary intake refers to n-3 from food items whilst supplementary intake refers to n-3 from supplement use
Mg = milligrams; NB = net benefit; TPR = true positive rate; FPR = false positive rate; TNR = true negative rate; FNR = false negative rate; PPV = positive predictive value; NPV = false negative value; n-3 = omeg-3; LCPUFA = long-chain polyunsaturated fatty acids

ISSN: 1471-2393